Creating a Global Company

Our Specialty Portfolio Indication For plaque psoriasis SUN PHARMA Ilumya/ Ilumetri Cequa • Launched in US in October 2018 & in Australia in Dec-2018, Phased launch in Europe by Almirall starting December 2018 onwards • Long term clinical data shows that the significant response rate seen in 52 & 64 weeks were maintained over five years • Winlevi Absorica LD • Evaluating new indications for Ilumya - Phase-2 data shows potential to improve joint & skin symptoms of Psoriatic Arthritis. Commenced Phase-3 trials in 2020 Out licensed to CMS for Greater China market & to Hikma for Middle East & North African markets • Launched in Japan in September 2020 and in Canada in October 2021 •Indication For dry eye disease • Launched in US in October 2019 • Out-licensed to CMS for Greater China market in June 2019 • Launched in Canada in January 2022 For the topical treatment of acne vulgaris in patients 12 years of age and older Launched in US in November 2021 • Indication - For the treatment of severe recalcitrant nodular acne that cannot be cleared up by any other acne treatments, including antibiotics. • Launched in US in February 2020 • Indication - In combination with BLU-U (Blue Light Photodynamic Therapy Illuminator) for treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities. Levulan Kerastick • Currently marketed in US for actinic keratosis 8

View entire presentation